Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Nasdaq

10 Consumer Discretionary Stocks Whale Activity In Today's Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

Benzinga

10 Information Technology Stocks Whale Activity In Today's Session

Benzinga

How To Attend Intellia Therapeutics Q1 2022 Earnings Conference Call

Intellia Therapeutics (NASDAQ:NTLA) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings Outlook For Fulgent Genetics

Fulgent Genetics (NASDAQ:FLGT) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Fulgent Genetics will report an earnings per share (EPS) of $3.86.

Benzinga

Where ON Semiconductor Stands With Analysts

Analysts have provided the following ratings for ON Semiconductor (NASDAQ:ON) within the last quarter:

Benzinga

Where Match Group Stands With Analysts

Within the last quarter, Match Group (NASDAQ:MTCH) has observed the following analyst ratings:

Benzinga

Veritone's Earnings Outlook

Veritone (NASDAQ:VERI) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Veritone will report an earnings per share (EPS) of $-0.10.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Preview: Rigel Pharmaceuticals's Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Rigel Pharmaceuticals will report an earnings per share (EPS) of $-0.14.

Benzinga

Analyst Ratings for Dada Nexus

Dada Nexus (NASDAQ:DADA) has observed the following analyst ratings within the last quarter:

Benzinga

Earnings Outlook For Varex Imaging

Varex Imaging (NASDAQ:VREX) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Varex Imaging will report an earnings per share (EPS) of $0.23.

Benzinga

Here's How Much $1000 Invested In Texas Instruments 15 Years Ago Would Be Worth Today

Texas Instruments (NASDAQ:TXN) has outperformed the market over the past 15 years by 4.19% on an annualized basis producing an average annual return of 11.09%. Currently, Texas Instruments has a market capitalization of $157.15 billion.

Benzinga

4 Analysts Have This to Say About Automatic Data Processing

Automatic Data Processing (NASDAQ:ADP) has observed the following analyst ratings within the last quarter:

Benzinga

Earnings Preview: XP

XP (NASDAQ:XP) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that XP will report an earnings per share (EPS) of $0.32.

Benzinga

EchoStar Earnings Conference Call Is Coming Up, Here's What You Need To Know

EchoStar (NASDAQ:SATS) will host a conference call at 11:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend EchoStar (SATS) Conference Call Follow this link to access the live webcast.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Insurance Stocks Moving In Monday's Intraday Session

According to Benzinga Pro following are the gainers and losers in Insurance industry for today's Intraday session.

Benzinga

PreMarket Prep Stock Of The Day: Buffett's Risk-On Approach To Activision Blizzard

At the annual meeting for Warren Buffett’s Berkshire Hathaway (NYSE: BRK-A)(NYSE: BRK-B), it was announced his firm

Benzinga

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

Benzinga

Why Nikola Shares Are Trading Lower Today

Nikola Corp (NASDAQ:NKLA) disclosed that an institutional investor has agreed to make a $200 million investment by purchasing Convertible Senior Notes. Funds advised by Antara Capital LP have agreed to purchase a $200 million aggregate amount of Convertible Senior Notes due 2026. The Notes will bear interest at a rate of 8.00% if…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Moderna Bullish On COVID-19 Vaccine For Younger Kids To Be Ready Next Month: Reuters

Moderna Inc's (NASDAQ:MRNA) chief medical officer said that its COVID-19 vaccine for children under six years old would be ready for review by the FDA panel when it meets in June. "I think the FDA now has all of the core fundamental data they need to be able to begin an application review.…

Benzinga

Endo Acquires Six Development-Stage, Injectable Product Candidates For $35M

Endo International plc (NASDAQ: ENDP) has acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc, a subsidiary of Nevakar Inc.

Benzinga

Vertex Pharma's Stem Cell Derived Diabetes Treatment Trial Put On Hold

The FDA has instituted a clinical hold on Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) VX-880 Phase 1/2 study due to a determination that there is insufficient information to support dose escalation with the product. VX-880 is an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for type 1 diabetes (T1D). Three patients have been…

Benzinga

Horizon Therapeutics' Inebilizumab Scores European Approval For Spinal Cord Inflammation

The European Commission has approved Horizon Therapeutics plc's (NASDAQ:HZNP) Uplizna (inebilizumab) as monotherapy for neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive (AQP4-IgG+). NMOSD is an autoimmune disease that attacks the optic nerve, spinal cord, brain, and brain stem. In the N-MOmentum pivotal clinical trial, Uplizna demonstrated a significant reduction…

Benzinga

Sage Therapeutics, Biogen Start Rolling Submission For Zuranolone In Major Depressive Disorder

Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) have initiated a rolling submission of a marketing application to the FDA for zuranolone in major depressive disorder (MDD). Zuranolone is an investigational two-week, once-daily oral drug developed for MDD and postpartum depression (PPD). The companies have submitted the nonclinical module and plan to submit the remaining…

Benzinga

Farmmi Wins New Export Order

Farmmi Inc (NASDAQ:FAMI) has won a new North American sales order to Vancouver, Canada. The order is for dried Shiitake mushrooms. The financial terms were not disclosed. “With the reopening of most cities worldwide following COVID shutdowns, we are seeing a pick-up from both consumption at restaurants and in-home cooking,” said Chairwoman and…

Benzinga

Apple Under Antitrust Allegations in Brussels

Brussels regulators have accused Apple Inc (NASDAQ:AAPL) of abusing its dominant position in mobile payments to limit rivals’ access to contactless technology. Apple could face a fine of up to 10% of its global turnover or $36.6 billion based on its 2021 revenue for the alleged breach of EU competition law. Also Read: Apple To…

1 … 658 659 660 661

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.